Topoisomerase I inhibitor 12 

Topoisomerase I inhibitor 12 (compound 12), a Camptothecin (HY-16560)-based derivative, is a potent Topoisomerase I inhibitor. Topoisomerase I inhibitor 12 shows anticancer activity^[1].

Topoisomerase I inhibitor 12 (compound 12) shows moderate antiproliferative activity against the MDA-MB-231, DU-145, HCT-116, SKOV-3, and SAOS-2 cancer cell lines (with IC₅₀ values of 5.96±0.03, 3.81±1.37, 3.67±0.21, 3.48±1.02, and 3.20±0.21 µM, respectively), as well as potent activity against the HOS (osteosarcoma) cancer cell line (IC₅₀=1.47 µM) while the potential of Topoisomerase I inhibitor 12 against fibroblast normal cells (BJ1) demonstrated a 2.89-fold selectivity (IC₅₀=4.25 µM) against cancer cell^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

402.45

C₂₃H₂₂N₄O₃

O=C1N2C(N(CCN3CCOCC3)C(/C2=C\C4=CC=CC=C4)=O)=NC5=CC=CC=C51

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ahmed I. Khodair, et al. Camptothecin structure simplification elaborated new imidazo[2,1-b]quinazoline derivative as a human topoisomerase I inhibitor with efficacy against bone cancer cells and colon adenocarcinoma. European Journal of Medicinal Chemistry. 16 December 2023, 116049.